RSLS: ReShape Lifesciences Inc. Company Sales Revenue

The sales structure and volume of ReShape Lifesciences (RSLS) help assess the moderate cyclicality of demand for minimally invasive devices used in obesity treatment. The business relies on the Lap-Band safety standard, offering effective weight loss. The environmental profile is based on sterility and proper waste disposal. The value of 0.01 sets the current metric, capturing daily operational product sales results.

Revenue and Sales Volume: ReShape Lifesciences, Inc. (RSLS) for 07/04/2022 - 08/30/2025

Comprehensive metric breakdowns and analytics for ReShape Lifesciences, Inc. (RSLS)

- stock value and consensus price forecast:

Stock Quotes ReShape Lifesciences Inc|RSLS - Consensus Target

- market capitalization information:

Market Value ReShape Lifesciences Inc.|RSLS - Total Company Value

- balance sheet net asset value indicators:

Accounting Value per Share ReShape Lifesciences|RSLS - Book Capitalization|Market-to-Book Ratio reshapelifesciences.com|RSLS - Company Total Assets

- company liabilities and liquidity data:

- company profitability and valuation multiples indicators:

RSLS - Net Income|Expected Net Income ReShape Lifesciences|RSLS - P/E Multiple|Projected Price to Earnings Ratio ReShape Lifesciences Inc|RSLS - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Multiple ReShape Lifesciences Inc.|RSLS - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) ReShape Lifesciences|RSLS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months reshapelifesciences.com|RSLS - Earnings per share growth in current year|Net earnings per share change forecast for next year ReShape Lifesciences

- company sales and revenue statistics:

RSLS - Company Revenue|Company Future Sales Volume ReShape Lifesciences Inc|RSLS - P/S Multiple|Market Cap to Future Revenue Ratio ReShape Lifesciences Inc.

Summary company analysis:RSLS reshapelifesciences.com

Product sample of reshapelifesciences.com

Operating revenues objectively record real demand for products, allowing investors to filter out market noise and assess the fundamental stability of the business. The current sales figure for ReShape Lifesciences (RSLS) at 0.01 reflects the effectiveness of the commercialization of Lap-Band systems and the implementation of new non-invasive obesity treatments, directly linking financial results to the sales volume of specialized medical equipment.

Key competitors